Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4079495 | 0.97 | CES2 (0.48) | CES2CES1NOS2HDAC8HDAC6 | |
| SCHEMBL163416 | 0.97 | CES2 (0.48) | CES2CES1NOS2HDAC8HDAC6 | |
| SCHEMBL3114031 | 0.97 | CES2 (0.48) | CES2CES1NOS2HDAC8HDAC6 | |
| SCHEMBL4743865 | 0.95 | — | — | |
| SCHEMBL730807 | 0.89 | TDP1 (0.38) | NOS2KDM4EMAPTKMT2AATM | |
| SCHEMBL543402 | 0.89 | — | — | |
| SCHEMBL6360577 | 0.80 | EPHX2 (0.34) | NOS2TDP1 | |
| Propane SCHEMBL28407353 | 0.80 | SMN1; SMN2 (0.38) | NOS2KMT2ATDP1GAA | |
| SCHEMBL20272049 | 0.80 | TDP1 (0.32) | NOS2TDP1 | |
| SCHEMBL29947305 | 0.78 | CHEK2 (0.32) | KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202366-B2 | Methods of promoting wound healing using CRM1 inhibitors | Karyopharm Therapeutics Inc. (US) | 2019-02-12 | — | — | US | claimed |
| EP-2414456-B1 | DEGRADABLE POLYMER COMPOSITIONS AND USES THEREOF | ISP INVESTMENTS LLC (US) | 2018-12-26 | — | — | EP | claimed |
| WO-2014088850-A2 | SHALE SWELLING INHIBITORS | ISP INVESTMENTS INC. (US) | 2014-06-12 | — | — | WO | claimed |
| EP-2414456-A1 | DEGRADABLE POLYMER COMPOSITIONS AND USES THEREOF | Isp Investments Inc. (US) | 2012-02-08 | — | — | EP | claimed |
| EP-2346909-A1 | POLYMERS DERIVED FROM N-VINYL FORMAMIDE, VINYL AMIDES OR ACRYLAMIDES, AND REACTION SOLVENT, AND THE USES THEREOF | Isp Investments Inc. (US) | 2011-07-27 | — | — | EP | claimed |
| WO-2010114761-A1 | DEGRADABLE POLYMER COMPOSITIONS AND USES THEREOF | ISP INVESTMENT INC. (US) | 2010-10-07 | — | — | WO | claimed |
| WO-2010056934-A1 | POLYMERS DERIVED FROM N-VINYL FORMAMIDE, VINYL AMIDES OR ACRYLAMIDES, AND REACTION SOLVENT, AND THE USES THEREOF | ISP INVESTMENTS INC. (US) | 2010-05-20 | — | — | WO | claimed |
| EP-4673447-A1 | [1,3]THIAZOLO[4,5-D]-PYRIMIDIN-7-ONES AS INHIBITORS OF NOX4 | Boehringer Ingelheim International GmbH (DE) | 2026-01-07 | — | — | EP | disclosed |
| US-20250188201-A1 | CATALYST FOR PHOTOCATALYTIC POLYMERIZATION REACTION, AND APPLICATION THEREOF | BEIJING INSTITUTE OF FASHION TECHNOLOGY (CN) | 2025-06-12 | — | — | US | disclosed |
| US-20240327429-A1 | [1,3]Thiazolo[4,5-d]-pyrimidon-7-ones as inhibitors of NOX4 | BOEHRINGER INGELHEIM INT (DE) | 2024-10-03 | — | — | US | disclosed |
| WO-2024180018-A1 | [1,3]THIAZOLO[4,5-D]-PYRIMIDIN-7-ONES AS INHIBITORS OF NOX4 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-09-06 | — | — | WO | disclosed |
| CN-116813823-A | Supported catalyst, preparation method thereof and application thereof in photocatalytic polymerization | 北京服装学院 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023169566-A1 | CATALYST FOR PHOTOCATALYTIC POLYMERIZATION REACTION, AND APPLICATION THEREOF | 北京服装学院 | 2023-09-14 | — | — | WO | disclosed |
| CN-102089291-A | Cyclopentyl acrylamide derivative | TEIJIN PHARMA LTD | 2011-06-08 | — | — | CN | disclosed |
| CN-102089291-A | Cyclopentyl acrylamide derivative | TEIJIN PHARMA LTD | 2011-06-08 | — | — | CN | disclosed |
| WO-2010056934-A1 | POLYMERS DERIVED FROM N-VINYL FORMAMIDE, VINYL AMIDES OR ACRYLAMIDES, AND REACTION SOLVENT, AND THE USES THEREOF | ISP INVESTMENTS INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-1147076-B1 | ACRYLAMIDE DERIVATIVES AND POLYMERS CONTAINING SAID DERIVATIVES | OKANO TERUO PROF (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-6495645-B1 | INCORPORATING MANY SIDE FUNCTIONAL GROUPS WHILE MAINTAINING SENSITIVE TEMPERATURE RESPONSE | Okano, Terou (JP) | 2002-12-17 | — | — | US | disclosed |
| EP-1147076-A1 | ACRYLAMIDE DERIVATIVES AND POLYMERS CONTAINING SAID DERIVATIVES | Amersham Pharmacia Biotech K.K. (JP) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000043355-A1 | ACRYLAMIDE DERIVATIVES AND POLYMERS CONTAINING SAID DERIVATIVES | AMERSHAM PHARMACIA BIOTECH K.K. (JP) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327429-A1 | [1,3]Thiazolo[4,5-d]-pyrimidon-7-ones as inhibitors of NOX4 | NOX4, NOX1, NOX5 | CES2 2470/4885CES1 1794/4885NOS2 570/4885 |
| US-10202366-B2 | Methods of promoting wound healing using CRM1 inhibitors | XPO1, XPA, ERCC2 | CES2 3919/4885CES1 2464/4885NOS2 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.